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Abstract Micromolar concentrations of tolbutamide will inhibit
(SUR1/KIR6.2)4 channels in pancreatic L-cells, but not (SUR2A/
KIR6.2)4 channels in cardiomyocytes. Inhibition does not require
Mg2+ or nucleotides and is enhanced by intracellular nucleotides.
Using chimeras between SUR1 and SUR2A, we show that
transmembrane domains 12^17 (TMD12-17) are required for
high-affinity tolbutamide inhibition of KATP channels. Deletions
demonstrate involvement of the cytoplasmic N-terminus of
KIR6.2 in coupling sulfonylurea-binding with SUR1 to the
stabilization of an interburst closed configuration of the channel.
The increased efficacy of tolbutamide by nucleotides results from
an impairment of their stimulatory action on SUR1 which
unmasks their inhibitory effects. The mechanism of inhibition of
L-cell KATP channels by sulfonylureas during treatment of non-
insulin-dependent diabetes mellitus thus involves two compo-
nents, drug-binding and conformational changes within SUR1
which are coupled to the pore subunit through its N-terminus and
the disruption of nucleotide-dependent stimulatory effects of the
regulatory subunit on the pore. These findings uncover a
molecular basis for an inhibitory influence of SUR1, an ATP-
binding cassette (ABC) protein, on KIR6.2, a ion channel subunit.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
The inhibition of KATP channels in pancreatic L-cells by
micromolar concentrations of tolbutamide or nanomolar con-
centrations of glibenclamide [1] has been the pharmacological
basis for treatment of non-insulin-dependent diabetes mellitus
with these ¢rst and second generation sulfonylureas for almost
60 years [2]. The high-a⁄nity sulfonylurea receptor SUR1 is
an ATP-binding cassette (ABC) protein [3] that associates
with the inward recti¢er, KIR6.2 [4], to form the octameric,
(SUR1/KIR6.2)4 L-cell KATP channel [5,6]. These channels
provide a unique example of functional coupling between an
ABC or transport ATPase protein and a KIR pore forming
subunit [7] and are the paradigm for other (SURx/KIR6.0)4
KATP channels [8].
Sensitivity to micromolar concentrations of tolbutamide,
poor reversibility of high-a⁄nity inhibition by nanomolar
concentrations of glibenclamide and enhancement of the sul-
fonylurea block by intracellular MgADP are hallmarks of L-
cell [9] but not cardiac KATP channels [10]. Reconstitution of
sarcolemmal KATP channels by co-expression of KIR6.2 and
SUR2A, a low-a⁄nity glibenclamide receptor, demonstrated
that the di¡erential response to sulfonylureas was speci¢ed by
the SUR isoform [11]. These data and the fact that glibencla-
mide consists of the tolbutamide moiety plus the non-sulfo-
nylurea meglitinide group known to inhibit KATP channels
[12,13] imply that SUR1 contains a high-a⁄nity tolbuta-
mide-binding site missing in SUR2A. Sulfonylureas do not
block the open pore of a KATP channel or a¡ect its unitary
conductance or intraburst kinetics. Sulfonylureas do shorten
the mean burst duration and lengthen the intervals between
bursts by placing channels in long-lived interburst closed
states [14]. The structural determinants involved in coupling
sulfonylurea-binding with closure of the (KIR6.2)4 pore are
unknown. How intracellular nucleotides increase the e⁄cacy
of sulfonylurea inhibition of L-cell channels is unknown [15].
Two reports suggest that sulfonylureas can alter the ADP
stimulation of SUR1/KIR6.2, but not SUR2A/KIR6.2 chan-
nels [16,17] and reduce the stability of 8-azido ATP-binding
to SUR1 [18]. These e¡ects are dependent on Mg2 and re-
quire intact nucleotide-binding folds (NBFs), suggesting that
sulfonylurea-binding can uncouple Mg-nucleotide di- and tri-
phosphate-dependent stimulatory e¡ects of SUR1 on the
KIR6.2 gate. As these stimulatory e¡ects antagonize nucleo-
tide inhibition on KIR6.2, uncoupling unmasks the inhibitory
action of nucleotides prompting KATP channel closure.
Using matched chimeras of human SUR1 and SUR2A, we
show that the transmembrane domains 12^17 (TMD12-17)
segment of SUR1 confers the high-a⁄nity component of tol-
butamide inhibition to chimeric SUR/KIR6.2 channels. High-
a⁄nity tolbutamide attenuation of channel activity does not
require the addition of Mg2 and nucleotides. Progressive
truncations of the N-terminus of KIR6.2 impair inhibition
by tolbutamide or glibenclamide, implying that the N-termi-
nus is involved in the allosteric coupling of conformational
changes in SUR1 to the gate of the pore, consistent with the
importance of this cytoplasmic domain for limiting channel
bursting [19]. A relationship between the degree of nucleotide
stimulation and tolbutamide inhibition demonstrates that sul-
fonylureas impair the stimulatory action of intracellular nu-
cleotides unmasking their inhibitory action. Our results sug-
gest a two component mechanism for the high-a⁄nity e¡ects
of sulfonylureas: binding to the TMD12-17 segment of SUR1
causes conformational changes that stabilize an interburst
closed con¢guration via a link that involves the N-terminus
of KIR6.2. The same conformational changes are proposed to
impair the stimulatory interactions of intracellular nucleotides
with the NBFs of SUR1 that balance the inhibitory e¡ects of
nucleotides on KIR6.2.
The results were presented at the 1998 Gordon Research
Conference on Cardiac Regulatory Mechanisms, Ion Channel
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Structures and Function and 43rd Biophysical Society Meet-
ings [20].
2. Materials and methods
The human SUR1, SUR2A and KIR6.2 cDNAs have been de-
scribed previously [21], as have the vNKIR6.2 and KIR6.2vC con-
structs [19,22] and the matched SUR chimeras [23]. Two additional
chimeras, XVII and XVIII, were generated as follows using the con-
structs shown in Fig. 2A. Chim XVII was constructed by replacing a
SalI-NotI fragment from Chim XIII, containing the N-terminus of
SUR1 with the SalI-NotI fragment from Chim IV which contains
the N-terminal half of SUR2 and TMD12-17 from SUR1. Chim
XVIII was constructed using overlapping PCR primers to engineer
a HindIII site into SUR2A to match one in SUR1. This changed
SUR2 residues R1197 and M1198 in the intermediate vector to K
and L, respectively. A HindIII-HindIII fragment from SUR1, contain-
ing residues 1020^1226, was then used to replace the corresponding
fragment in the intermediate vector to generate Chim XVIII. The
resulting plasmids were sequenced in both directions to verify that
no mutations were introduced. The transfection and cultivation of
COSm6 cells for electrophysiological experiments and the recording
of currents using the patch-clamp technique were done as described
previously [24]. All recording was done using an Axopatch 200B am-
pli¢er (Axon Instruments, Foster City, CA, USA), at 340 mV hold-
ing and 23^24‡C unless otherwise noted. Pipettes were ¢lled with the
K-rich external solution containing (mM): KCl 145, MgCl2 1, CaCl2
1, HEPES 10, pH 7.4 (KOH), unless otherwise noted. The Mg2-free
internal solution contained (mM) KCl 140, EDTA 5, HEPES 5, KOH
10, pH 7.2 (KOH), while the Mg2-containing ‘intracellular’ solution
had the following composition (mM): KCl 140, MgCl2 1, EGTA 5,
HEPES 5, KOH 10, pH 7.2 (KOH). The free Mg2 concentration in
the Mg2-containing internal solution supplemented with nucleotides
was kept at a quasi-cytosolic level of V0.7 mM by adding MgCl2 to
account for the Mg2-binding to nucleotides [25]. Nucleotides and
other compounds were from Sigma (St. Louis, MO, USA). Bathing
solutions were applied using a programmable rapid solution changer
(RSC-200, Biologic, Claix, France). The relative NPo, used as a meas-
ure of channel activity in the presence of a test compound, was esti-
mated and the single channel kinetics and nucleotide-sensitivity were
analyzed as described earlier [24]. A conventional single pseudo-Hill
equation or a two component pseudo-Hill equation were ¢t to the
tolbutamide dose-response data. The latter included the fraction of
the maximal NPo (L) remaining when all of the high-a⁄nity inhib-
itory sites are occupied [17] and the concentrations IC50h and IC50l at
which inhibition is half maximal at the high and low-a⁄nity sites with
corresponding hh and hl slope factors, respectively. Non-linear curve
¢tting was done using the Marquardt-Levenberg algorithm. Averaged
data are expressed as means þ S.E.M. for nv5 with error bars equal to
the S.E.M., unless otherwise noted. Signi¢cance was evaluated using
the Student’s t test. Di¡erences with values of P6 0.05 were consid-
ered to be signi¢cant.
3. Results
3.1. SUR1 speci¢es high-a⁄nity tolbutamide inhibition, which
is enhanced by stimulatory nucleotides
Fig. 1A shows that inhibition of SUR1/KIR6.2 channels by
tolbutamide, in the absence of nucleotides, can be described
by a two site model where the IC50h and IC50l values di¡er by
approximately three orders of magnitude, 1.9 þ 0.2 WM
(hh = 1.04 þ 0.08) versus IC50L = 1399 þ 137.3 WM (hl = 1.13 þ
0.1). Inhibition of the SUR2A/KIR6.2 channels can be de-
scribed by a single site model with an IC50 value,
1057.4 þ 52.1 WM (hl = 0.95 þ 0.04), similar to the low-a⁄nity
site in the SUR1/KIR6.2 channels, in agreement with our ear-
lier estimate [24]. Comparable results were found for channels
reconstituted from rat SUR1 or SUR2A plus mouse KIR6.2 in
Xenopus oocytes [17]. The results are consistent with the idea
that the high sensitivity of the L-cell KATP channel to sulfo-
Fig. 1. SUR1 speci¢es the high-a⁄nity tolbutamide inhibition of
KATP channels which is enhanced by Mg-nucleotides. A: A compar-
ison of the currents and tolbutamide dose-response curves from
SUR1/KIR6.2 versus SUR2A/KIR6.2 KATP channels indicates that
the L-cell channel can be described by two components versus a sin-
gle component for the cardiac channel. The solid curve through the
SUR1/KIR6.2 data is the best ¢t to a two component pseudo-Hill
equation giving IC50h = 1.9 þ 0.2 WM, hh = 1.04 þ 0.08, IC50l = 1399 þ
137.3 WM, hl = 1.13 þ 0.1 and L = 0.451 þ 0.015. The dashed line
through the SUR2A/KIR6.2 data is the best ¢t to a single compo-
nent pseudo-Hill equation giving IC50 = 1057.4 þ 52.1 WM and
h = 0.95 þ 0.04. These experiments were done in the absence of nu-
cleotides in the Mg2-containing internal solution described in Sec-
tion 2. B: The addition of ADP to the ATP-containing internal sol-
ution at V0.7 mM free Mg2 stimulates SUR1/KIR6.2 channels
and markedly increases the degree of high-a⁄nity tolbutamide in-
hibition. Here and in the following ¢gures, the arrow and i-o indi-
cate isolation of the inside-out patch, a downward de£ection of the
current trace corresponds to inwardly directed current, the horizon-
tal dotted lines show the level of current when all KATP channels
are closed and the thick solid lines indicate superfusion with a test
compound at the concentration shown. Tlb = tolbutamide. The high-
er ratio of the mean current to macrocurrent noise for SUR2A/
KIR6.2 channels is consistent with the cardiac channels having a
higher Pomax [23].
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nylureas is determined by a high-a⁄nity sulfonylurea-binding
site in SUR1 [3] missing in SUR2A [11,17,24]. Low-a⁄nity
inhibition of the SUR1/KIR6.2 channels is attributed to an
interaction of sulfonylureas with KIR6.2 [17]. The data are
not su⁄cient to conclude that low-a⁄nity binding of tolbuta-
mide to SUR2A [26] makes no contribution and that inhi-
bition is entirely due to binding to KIR6.2. High-a⁄nity in-
hibition of SUR1/KIR6.2 channels, speci¢ed by sulfonylurea-
binding to SUR1, is saturated at V40% of the maximal Po
in the absence of nucleotides (Pomax) by V100 WM tolbuta-
mide. A substantial channel activity remains at several mM
tolbutamide. Two-hundred WM tolbutamide was used to sat-
urate the high-a⁄nity tolbutamide-binding site in all further
experiments.
Fig. 1B illustrates the enhancing e¡ect of a quasi-intracel-
lular mixture of ADP and ATP at V0.7 mM free Mg2 on
the inhibition of reconstituted human L-cell KATP channels by
200 WM tolbutamide. Using these simulated intracellular con-
Fig. 2. Delineation of the SUR1 segment required for high-a⁄nity tolbutamide inhibition of KATP channels. A: The top panel shows inhibition
of channels assembled from KIR6.2 and SUR1, SUR2A or the chimeric SURs illustrated. Chimeras I^VI and IX^XIV were described in a pre-
vious report [23]. The topological features of SUR are given on the left, the corresponding amino acids on the right axis. Segments from
SUR1 and SUR2A are shown in white and gray, respectively. The presence of TMD12-17 from SUR1 is su⁄cient to confer a high-a⁄nity in-
teraction with tolbutamide. B: The inset gives a representative example of inhibition of the Chim XVII/KIR6.2 channel. These channels contain
TMD1-5 which speci¢es the higher Pomax of the cardiac channel [23], indicated by the greater ratio of the mean current to macrocurrent noise
(compare with Fig. 1A). The dose-response curves for the Chim XVII/KIR6.2 and Chim XVIII/KIR6.2 channels show that TMD12-17 from
SUR1 speci¢es a high-a⁄nity interaction with tolbutamide (IC50h = 2.2 þ 0.3 WM, hh = 1.11 þ 0.11, IC50l = 1374.1 þ 393.2 WM, hl = 0.97 þ 0.21,
compare with the values for SUR1 in Fig. 1). Reducing the size of the swapped segment reduces the apparent a⁄nity of the chimeric channel
for tolbutamide (IC50h = 16.7 þ 4.3 WM, hh = 1.18 þ 0.19, IC50l = 1504.6 þ 914.5 WM and hl = 1.01 þ 0.37) without signi¢cantly a¡ecting the ap-
parent e⁄cacy (L = 0.32 þ 0.029 versus 0.355 þ 0.092 for Chim XVII versus XVIII, respectively). The ionic conditions and holding potential are
as in Fig. 1.
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ditions [27], ADP stimulates channel activity pre-inhibited by
1 mM ATP, while 200 WM tolbutamide reduces channel ac-
tivity V10-fold compared with V2.5-fold inhibition in the
absence of nucleotides. Tolbutamide (200 WM) did not a¡ect
the unitary conductance or intraburst kinetics of SUR1/
KIR6.2 channels (see [19] for values obtained under similar
conditions). Note that comparable tolbutamide concentra-
tions will nearly eliminate the KATP conductance of whole
L-cells and that others have described the ‘enhanced’ inhibi-
tion of L-cell KATP channels when MgADP [9] or other nu-
cleotide di- or triphosphates are present at the cytoplasmic
face of isolated patches [15].
3.2. High-a⁄nity inhibition by tolbutamide requires the
TMD12-17 segment of SUR1
Matched SUR chimeras [23] were used to delineate the
region of SUR1 which confers high-a⁄nity tolbutamide inhi-
bition by comparing the e¡ect of 200 WM tolbutamide on
chimeric channels (Fig. 2A). The results indicate that the
TMD12-17 segment of SUR1 is critical for high-a⁄nity tol-
butamide inhibition. Ash¢eld et al. [28] reported a similar
result using unmatched chimeras. Chim XVII and XVIII
show that TMD12-17 is su⁄cient to confer high-a⁄nity in-
hibition when swapped into SUR2A. Comparison of the tol-
butamide dose-response curves for the Chim XVII/KIR6.2 and
Fig. 3. Deletion of the N-terminus of KIR6.2 impairs high-a⁄nity sulfonylurea inhibition. A: Deletion of 32 amino acids, vN32, from the N-
terminus of KIR6.2 eliminates high-a⁄nity inhibition of L-cell KATP channels, but not low-a⁄nity tolbutamide inhibition, or stimulation by di-
azoxide and nucleotides. Mg-nucleotides also stimulated all chimeric channels. B: Progressive truncation of the N-terminus of KIR6.2 results in
a gradual impairment of high-a⁄nity inhibition to the level of SUR2A/KIR6.2 channels marked here by the thick dashed and dotted lines
(mean þ S.D.). C: N-terminal deletion progressively eliminates the inhibitory action of glibenclamide. The holding potential was 0 mV. The qua-
si-physiological external pipette solution contained (mM): NaCl 140, KCl 5, MgCl2 1, CaCl2 1, HEPES 10, pH 7.4 (NaOH). The single chan-
nel kinetics, ATP- and tolbutamide-sensitivity of the SUR1/vN44KIR6.2 channels using similar experimental conditions were reported previ-
ously [7,19]. Free [Mg2] in the internal solution was V0.7 mM.
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Chim XVIII/KIR6.2 channels (Fig. 2B) show that the smaller
TMD12-15 segment reduces the a⁄nity for tolbutamide with-
out a¡ecting the e⁄cacy of high-a⁄nity inhibition (1-L), con-
sistent with a tolbutamide-binding site within TMD12-17. Our
previous studies [23] have shown that the TMD1-5 segment,
not the TMD12-17 segment, speci¢es the L-cell versus sarco-
lemmal channel isoform di¡erences in Pomax. Di¡erences in
Pomax are determined by the occupancy of interburst closed
state(s), suggested to be the key state(s) that bind nucleotides
and sulfonylureas that inhibit KATP channels [19,29,30]. This
result and the observation that the intraburst kinetics of the
Chim XVII/KIR6.2 and Chim XVIII/KIR6.2 channels are sim-
ilar to those of wild-type channels [23] argue that changes in
tolbutamide-sensitivity of the chimeric channels can not solely
be due to modi¢cation of the single channel kinetics by swap-
ping TMD12-17 segments. The conservative conclusion is that
a part of the high-a⁄nity sulfonylurea-binding site is formed
by the TMD12-17 segment of SUR1.
3.3. The N-terminus of KIR6.2 is involved in coupling
sulfonylurea-binding to SUR1 with closure of the KATP
channel pore
We have shown previously that truncation of the N-termi-
nus of KIR6.2 increases the Pomax of L-cell KATP channels by
reducing the occupancy of the interburst closed state [19].
Truncation moderately increases the apparent IC50ATP
[19,31], but millimolar concentrations of ATP will reduce
the Po to nearly undetectable levels. The e¡ects of N-terminal
deletions have not been observed for homomeric KIR6.2vC
channels [31] whose steady-state ATP-sensitivity is lower
than that of SUR1/vNKIR6.2vC channels (see [22] versus
[19] for a statistically representative side by side comparison
of KIR6.2vC versus SUR1/vNKIR6.2vC channels). The re-
sults indicate that deletion of as many as 44 amino acids
from the N-terminus [19] does not a¡ect closure of the pore
or remove the low-a⁄nity nucleotide site from KIR6.2, but
does disrupt functional coupling between SUR and KIR6.2
[7]. The results shown in Fig. 3 support this hypothesis. As
illustrated in Fig. 3A, SUR1/vN32KIR6.2 channels are inhib-
ited by 200 WM tolbutamide as poorly as the SUR2A/KIR6.2
channels (relative NPo values of 0.84 þ 0.03 versus 0.82 þ 0.05,
respectively). At the same time, the SUR1/vN32KIR6.2 chan-
nels were stimulated by ADP or the potassium channel opener
diazoxide (300 WM), in the presence of ATP and Mg2. Tol-
butamide at a high concentration (5 mM) inhibited SUR1/
vN32KIR6.2, SUR1/vN32KIR6.2vC35 and SUR2A/KIR6.2
channels equivalently in the absence of Mg-nucleotides (rela-
tive NPo values of 0.16 þ 0.05, 0.18 þ 0.07 and 0.17 þ 0.06,
respectively). These values are consistent with the IC50 for
tolbutamide inhibition reported for KIR6.2vC26 channels
[17], arguing that the deleted segments of the N- and C-ter-
mini of KIR6.2 are not part of the low-a⁄nity tolbutamide-
binding site. Fig. 3B summarizes the data for a series of dele-
tions. Truncation of as few as ¢ve amino acids was su⁄cient
to compromise high-a⁄nity tolbutamide inhibition. Trunca-
tion of 10 or 20 amino acids gave V85^90% of the maximum
attenuation of the inhibition. Analysis of the tolbutamide
dose-response of the SUR1/vN10KIR6.2 channels showed a
signi¢cantly increased L value (0.88 þ 0.028 versus
0.451 þ 0.015 for the wild-type channel shown in Fig. 2)
with no signi¢cant changes in the parameters related to tol-
butamide-binding (IC50h = 1.7 WM at hh = 1.36 and
IC50l = 1479.4 WM at hl = 0.97). As shown in Fig. 3C, high-
a⁄nity inhibition by glibenclamide was also impaired by N-
terminal deletion.
As reported for other SUR1/vNKIR6.2 channels [19], the
IC50ATP and Pomax values for the SUR1/vN10KIR6.2 chan-
nels were slightly increased, with about a 3-fold increase in the
steady-state IC50ATP (20.1 þ 2.8 WM, mean þ S.D. for n = 4
versus 5.9 þ 0.5 WM for wild-type channels) and approximately
a 10% increase in Pomax (by a direct estimate from three di¡er-
ent single channel records, see also a prediction from macro-
current analysis [31]). The decreased apparent ATP-sensitivity
of the SUR1/vNKIR6.2 channels could result from a de-
creased occupancy of interburst closed state(s) that bind
ATP [19]. Although a similar mechanism has been suggested
for the insensitivity of SUR1/KIR6.2C166S channels to 100 WM
tolbutamide [30], it is unlikely that a decreased occupancy of
the closed state(s) can explain the decreased fraction of the
high-a⁄nity component of tolbutamide inhibition seen for the
SUR1/vN10KIR6.2 channels. Reducing the Po of SUR1/
vNKIR6.2 channels to the Pomax of wild-type channels by
V5^10 WM ATP in Mg2-free conditions or by spontaneous
run-down did not increase the fraction of the high-a⁄nity
component of tolbutamide inhibition (LV0.85). Similarly, in-
creasing the Pomax of KATP channels with an intact KIR6.2 did
not a¡ect the fraction of the high-a⁄nity component. Chim
XVII (Fig. 2), like Chim II, contains the TMD1-5 segment of
SUR2A, which speci¢es higher Pomax values, and has a Pomax
value comparable to those of the SUR1/vN10KIR6.2 chan-
nels, which are greater than the Pomax values of SUR1/
KIR6.2 channels [23]. Irrespective of the lower occupancy of
the interburst closed state, the two chimeric channels were
inhibited by tolbutamide as e⁄ciently as wild-type channels
(a somewhat lower L was observed for Chim XVII/KIR6.2
channels, as shown in Fig. 2B). The latter results are not
complicated by the presence of nucleotides, by the possibility
of altered interactions between subunits in run-down channels
or by possible e¡ects of the KIR6.2 modi¢cation. The obser-
vation is consistent with the idea that coupling of tolbuta-
mide-binding with SUR1 to closure of the gate is not a purely
kinetic phenomenon and suggests a speci¢c role for the N-
terminus in transduction of an inhibitory signal from SUR1 to
the pore.
3.4. Sulfonylurea-binding to SUR1 impairs the stimulatory
action of intracellular nucleotides
Fig. 4A shows that the degree of inhibition by 200 WM
tolbutamide is always higher in the presence of Mg2 and
nucleotides (either ATP, ADP or both at variable ratios
with a quasi-cytosolic concentration of Mg2, V0.7 mM).
Inhibition of SUR1/KIR6.2 channels by glibenclamide (100
nM) is also enhanced by MgADP [17]. To test whether satu-
ration of the sulfonylurea-binding site on SUR1 could abolish
the stimulatory action of either, or both, ATP or ADP, we
compared the e¡ects of tolbutamide under stimulatory and
inhibitory conditions (presence of Mg-nucleotides versus pres-
ence of nucleotides without Mg2 plus 5 mM EDTA, respec-
tively). Each paired set of internal solutions was tested on a
membrane fragment selected for a high density of channels
and fast di¡usional access (comparable with that shown in
Fig. 4A) to increase the signi¢cance of current measurements
at millimolar concentrations of nucleotide(s) and to minimize
errors due to variable ‘fading’ of Mg-nucleotide stimulation of
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Fig. 4. Tolbutamide-binding uncouples the Mg-nucleotide-dependent stimulatory action of SUR1 on KIR6.2. A: The degree of high-a⁄nity in-
hibition of SUR1/KIR6.2 channel currents is greater in the presence of either MgATP, MgADP or both nucleotides as a result of their stimula-
tory action on SUR1 [27,46]. In a representative conventional inside-out patch containing V103 KATP channels, with fast di¡usional access,
200 WM tolbutamide inhibited the current 2.85, 5.32, 11.09 and 5.05-fold versus 1.95 þ 0.02-fold (mean þ S.D., two applications) in the presence
of 0.1 mM ATP, 0.2 mM ADP, 0.1 mM ATP plus 0.2 mM ADP, 1 mM ATP plus 0.4 mM ADP versus no nucleotides, respectively. The
measurements were done in Mg2-containing internal solution. Interestingly, fast di¡usional access to these channels allows for resolution of a
rapid current transient upon application of ADP, which may be the result of more rapid inhibition than stimulation. B: The enhancement of
high-a⁄nity tolbutamide inhibition of SUR1/KIR6.2 channels by MgATP and/or MgADP is the result of tolbutamide uncoupling the stimula-
tory action of Mg-nucleotides, thus accentuating their inhibitory action. Currents were recorded as described above. Note that the scales of rel-
ative NPo values change. The relative NPo values after tolbutamide inhibition in Mg2-containing and Mg2-free conditions were not signi¢-
cantly di¡erent. C: A plot of the tolbutamide-induced decrease in NPo in the presence of Mg-nucleotide(s) versus the Mg-nucleotide-stimulated
increase in NPo shows a correlation. The alphabetical symbols correspond to the individual experiments in (B). The solid line shows a linear
regression (RV1), the dashed lines give the 95% con¢dence limits. D: Tolbutamide inhibition of MgUDP-stimulated SUR1/KIR6.2 channel cur-
rents. MgUDP was applied before there was substantial run-down of SUR1/KIR6.2 channels. The strong stimulatory action of MgUDP seen at
this high, non-physiological concentration may be the result of a markedly reduced inhibitory action of UDP (estimated IC50UDPs 1 mM,
data not shown), rather than a unique stimulatory action (as was suggested originally for cardiac KATP channels [29]). Like MgADP, 10 mM
MgUDP produced a di¡usion-limited o¡set of the current followed by a rise to nearly the level of current seen after removal of 1 mM ATP
(in Mg2) used to refresh the channels (upward arrow). Removing Mg2 by perfusion with 5 mM EDTA (downward arrow) caused a minor
increase in activity which was inhibited by application of 10 mM UDP.
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KATP channels following patch excision [32]. A summary of
the results from a number of such experiments (Fig. 4B) illus-
trates three points. (1) Nucleotides alone do not a¡ect the
action of tolbutamide. The V2-fold inhibition by 200 WM
tolbutamide in the absence of Mg2 was similar to the degree
of inhibition seen in nucleotide-free conditions irrespective of
Mg2 (an example of tolbutamide inhibition in the absence of
nucleotides with Mg2 present is illustrated in Fig. 4A). (2)
Stimulatory Mg-nucleotides do not a¡ect the ¢nal level of
inhibition, irrespective of the nucleotide composition tested,
200 WM tolbutamide decreased the NPo to nearly the same
level in the presence or absence of Mg2. As a result, (3) the
degree of tolbutamide inhibition in the presence of Mg-nu-
cleotide(s) correlates with the degree of NPo increase stimu-
lated by Mg-nucleotides (Fig. 4C), arguing that saturation of
the sulfonylurea-binding site eliminates the stimulatory but
not the inhibitory action of Mg-nucleotides. This conclusion
is consistent with the observation that 100 WM tolbutamide
will ‘inhibit the channel activating e¡ect of MgGDP in a non-
competitive manner’ [33]. Fig. 4D illustrates a similar result
for SUR1/KIR6.2 channels stimulated maximally by 10 mM
MgUDP. Two-hundred WM tolbutamide eliminates stimulated
KATP channel activity when applied prior to signi¢cant run-
down of the current. In agreement with previous studies, we
Fig. 5. The proposed interactions involved in modulation of nucleotide-dependent gating of KATP channels by sulfonylureas. Two pairs of
SUR/KIR6.2 subunits, a cardiac pair on the left and a L-cell pair on the right, are illustrated around a central pore. The SURs surround
KIR6.2 consistent with absence of data, suggesting that they contribute to the permeation pathway. The triplet of dots indicates the location of
ER retention signals, which ensure that only completely assembled channels reach the plasma membrane [47]. Our chimeric channel data were
used to position the TMD domains based on the ¢nding that TMD1-5 speci¢es the isoform di¡erences in kinetics [23], which presumably re-
quires its closer proximity to the KIR6.2 gate. The C-terminus of SUR is placed near the C-terminal cytoplasmic segment of KIR6.2 based on
the speci¢cation of the isoform di¡erences in IC50ATP by the last 42 amino acids of SUR. The KIR pore is modeled on the bacterial KcsA
channel [40] without implying an exact packing of M1 and M2, which may be di¡erent in KIRs [48]. The K selectivity ¢lter is formed by the
backbone carbonyl groups ( = O) of the -GFG- motif. Two dehydrated K ions (smaller spheres) occupy the ¢lter, a larger hydrated K ion is
stabilized by pore helix dipoles in the central cavity [49]. The M2 internal helices line the aqueous canal within the transmembrane electrical
¢eld. ‘Gated access’ [39] to the pore is controlled by translation rotational movements of ‘rigid bodies’ composed of the K-helical M2 and possi-
bly the adjacent segment of the C-terminus [41]. A periodicity in cysteine accessibility to Cd2 in these segments [50] is consistent with the
model. Movement of the internal helices is indicated by their di¡erent positions in the two halves of the pore, the left pair is illustrated in an
open state with the M2 helix orientation allowing for ‘gated access’ to the pore. No inhibitory nucleotide is shown in the proposed low-a⁄nity
C-terminal ATP-binding site of KIR6.2 [51]. Both NBFs on SUR are occupied and are drawn to indicate cooperative interactions of Mg2-in-
dependent high-a⁄nity ATP-binding on NBF1 and low-a⁄nity MgADP-binding on NBF2 [18]. The right pair illustrates a closed state induced
by glibenclamide. The glibenclamide-binding site consists of a benzamido (meglitinide)-binding site (dotted benzene ring) on TMD1-5 and a sul-
fonylurea (tolbutamide)-binding site on TMD12-17, consistent with earlier observations [3] and the data presented here and in [28]. The higher
a⁄nity of the second generation sulfonylureas, like glibenclamide, for SUR presumably arises from binding at both sites. A molecule of tolbu-
tamide displaced by azido-iodoglibenclamide is shown. Cooperative interactions between NBF1 and NBF2 are disrupted by the conformational
change (shown here as a change in orientation of TMD1-5 and 12-17) induced by sulfonylurea-binding, consistent with the observations of
Ueda et al. [18]. This conformational switch repositions the M2 helix to form an interburst closed state. This requires an intact N-terminus on
KIR6.2. Thus, high-a⁄nity sulfonylurea inhibition of (SUR1/KIR6.2)4 channels in vivo is determined by an integration of the inhibitory signals
from occupied sulfonylurea-binding site(s) and from ATP inhibitory site(s), both of which stabilize a long-lived closed state of the (KIR6.2)4
pore.
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saw no stimulation of SUR1/KIR6.2 channels by nucleotide
monophosphates, which weakly inhibited (IC50s 1 mM, see
also [31]). We conclude that the increased e⁄cacy of sulfonyl-
ureas for KATP channels in L-cells is due to elimination of the
stimulatory action of intracellular nucleotide di- and triphos-
phates, thus accentuating their inhibitory action.
4. Discussion
Initial insight into how sulfonylureas work came with the
identi¢cation of KATP channels in L-cells [34] and the ¢nding
that their activity was inhibited by tolbutamide and by gliben-
clamide [1]. Several studies reported on the di¡erential sensi-
tivity of L-cell versus cardiac KATP channels to sulfonylureas
([9] versus [10]) and noted the enhancing e¡ects of Mg-nucleo-
tides for their action on L-cell KATP channels [9,15]. In this
study, we used tolbutamide, a reversible inhibitor, rather than
glibenclamide. The latter is nearly irreversible and is pharma-
cologically more complex since it contains both a sulfonylurea
moiety and the benzamido moiety of meglitinide, a compound
that inhibits both L-cell and SUR2A/KIR6.2 channels [17,35]
and may thus bind to SURs at a separate site [12,13,17,36].
Glibenclamide photolabelling of the TMD1-5 segment of
SUR1 [3] is consistent with a complex-binding site in which
the sulfonylurea moiety binds to TMD12-17 and the benza-
mido group is in close proximity to the TMD1-5 segment (see
Fig. 5). The simultaneous binding of second generation sulfo-
nylureas at two sites would account for their lower KD values
[26].
Comparison of dose-response curves shows that tolbuta-
mide reduces the Po of L-cell KATP channels through high-
and low-a⁄nity interactions, while low-a⁄nity interactions
account for inhibition of sarcolemmal channels (Fig. 1 and
[17]). The high-a⁄nity component requires SUR1 while the
low-a⁄nity component appears to be a direct e¡ect on
KIR6.2 [17]. It is not clear whether direct binding to KIR6.2
can account completely for the inhibition of SUR2A/KIR6.2
channels. Dorschner et al. [26] have estimated a KDV0.3 mM
for binding of tolbutamide to SUR2A and simulation of in-
hibition through two low-a⁄nity binding sites versus a single
site on KIR6.2 suggests that either model can account for the
available data. A binding site has not been localized on
KIR6.2, but 5 mM tolbutamide inhibits channels missing the
¢rst 44 and last 35 amino acids, indicating that they are not
critical. Similarly, the speci¢city of the low-a⁄nity site has not
been established. Meglitinide will inhibit homomeric
KIR6.2vC channels with an IC50V103 times greater than
for heteromeric channels [17], although the IC50 values for
inhibition of the heteromeric channels are consistent with
the a⁄nities of meglitinide for SUR1 and SUR2A [26]. It is
worth noting that inhibition of channel activity by supra-
pharmacological concentrations of sulfonylureas does not
mean that SUR/KIR type KATP channels are present and
should be used with caution to infer interactions between
SURs and KIRs.
We used chimeras between SUR1 and SUR2A to determine
the region of SUR1 important for the high-a⁄nity inhibitory
e¡ects of tolbutamide. Inclusion of the TMD12-17 segment of
SUR1 was su⁄cient to confer high-a⁄nity inhibition, while
swapping a shorter TMD12-15 segment into SUR2A in-
creased the IC50h V8-fold without decreasing the apparent
e⁄cacy of inhibition. Substitution of SUR1 TMD12-17 into
SUR2A did not a¡ect the occupancy of the interburst closed
state that is critical for interaction with inhibitory nucleotides
[19], implying that TMD12-17 speci¢es tolbutamide-binding
rather than coupling binding at a separate site, common to
SUR1 and SUR2, to KIR6.2. The speculation [17] that
SUR2A binds sulfonylureas as well as SUR1 (see for example
[37,38]) without closing the channel is eliminated by the ¢nd-
ing that [3H]P1075 is displaced from SUR2 by tolbutamide or
glibenclamide with estimated KD values of V0.3 mM or
V0.3 WM, respectively, values markedly higher than those
estimated for tolbutamide or glibenclamide displacement of
[3H]glibenclamide from SUR1 [26]. Furthermore, unpublished
data of Schwanstecher and colleagues suggest an essential
role for TMD12-17 from SUR1 for high-a⁄nity [3H]gliben-
clamide-binding.
Our observations are consistent with tolbutamide-binding
with a micromolar a⁄nity to TMD12-17 of SUR1, inducing
a conformational change with at least two consequences. (1)
The change is coupled directly to KIR6.2 through its N-termi-
nus, decreasing the Po by V60%. Deletions of 5^44 amino
acids from the N-terminus disrupt this high-a⁄nity inhibition,
but do not a¡ect the kinetics, ATP and low-a⁄nity tolbuta-
mide inhibition of homomeric KIR6.2vC channels. This direct
coupling does not require nucleotides or intact NBFs and
cannot be attributed to kinetic e¡ects, although a reduced
occupancy of the long-lived closed state has been suggested
to account for the insensitivity of SUR1/KIR6.2C166S channels
to tolbutamide [30]. Unlike the N-terminal deletions, this mu-
tation dramatically increases the Pomax and IC50ATP of ho-
momeric KIR6.2vC26 channels and appears to modify ‘gated
access’ to the pore [39], based on its role in gating of KcsA
channels [40,41]. Tolbutamide inhibition of SUR1/vNKIR6.2
channels partially pre-inhibited with ATP and of chimeric
channels displaying an increased Pomax demonstrates that a
normal occupancy of the interburst closed state does not
guarantee normal coupling of sulfonylurea-binding to stabili-
zation of the KIR6.2 pore in a long-lived closed conformation.
We suggest that the N-terminus couples the sulfonylurea-in-
duced conformational changes in SUR1 to the gate of KIR6.2
through an interaction with a C-terminal segment adjacent to
the M2-helix. This is consistent with recent evidence for a
cytoplasmic bundle whose rearrangement might a¡ect the po-
sitioning of the pore lining helices of bacterial channels during
gating [41,42]. (2) The conformation changes disrupt stimula-
tion of SUR1/KIR6.2 channel activity by Mg-nucleotides. At
variable concentrations of ATP and/or ADP, 200 WM tolbu-
tamide decreases SUR1/KIR6.2 channel activity to nearly the
same level in the presence or absence of Mg2. The ¢nal NPo
values depend on the nucleotide concentration and are close
to what is expected from adding the inhibitory e¡ects of nu-
cleotides to the V2-fold decrease in Po seen in the absence of
Mg-nucleotides described above. This two-part mechanism,
consisting of the action of tolbutamide plus the e¡ect of in-
hibitory nucleotides, predicts that the ‘apparent’ IC50 for sul-
fonylureas will inversely correlate with the nucleotide concen-
tration. This would explain the variable IC50 values for
sulfonylurea inhibition of KATP channels seen in whole L-
cell experiments versus estimates from excised patches (see,
for example, [43]) and the variation in apparent IC50 values
for sulfonylurea inhibition of SUR1/KIR6.2 channels in in-
side-out patches with the nucleotide concentration. Whether
Mg-nucleotides a¡ect the KD for sulfonylurea-binding is ques-
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tionable, but at least two reports suggest that Mg-nucleotides
inhibit sulfonylurea-binding, i.e. attenuating rather than ac-
centuating the e¡ects of these compounds [38,44]. We have
been unable to demonstrate a systematic e¡ect of nucleotides
on the binding of [125I]iodoglibenclamide to recombinant
SUR1 (Bryan, unpublished data). Our ¢nding that the degree
of tolbutamide inhibition in the presence of 0.1 mM
MgATP+0.2 mM MgADP is higher than in the presence of
1 mM MgATP+0.4 mM MgADP suggests that enhancement
cannot be explained solely by a nucleotide-dependent increase
in the a⁄nity of SUR1 for sulfonylureas.
How a tolbutamide-induced conformational change in
SUR1 disrupts the stimulation of SUR1/KIR6.2 channels by
Mg-nucleotides is unclear. Allosteric e¡ects that impair nu-
cleotide-binding at the NBFs and disruption of the coupling
between SUR1 and KIR6.2 are two possibilities. Although
disruption of coupling cannot be ruled out, allosteric e¡ects
are consistent with biochemical data indicating that glibencla-
mide a¡ects the stability of 8-azido ATP-binding on NBF1 of
SUR1 [18]. Ueda et al. [18] propose that KATP channels are
open when ATP is bound to NBF1 and MgADP occupies
NBF2 while binding of glibenclamide releases ATP from
NBF1, thus closing channels. The result is consistent with
tolbutamide-induced conformational changes being transmit-
ted through the N-terminus of KIR6.2 to the pore in the
absence of nucleotides, but are at variance with our observa-
tion that SUR1/KIR6.2 channels can be reversibly, and repeat-
edly, inhibited by tolbutamide in nucleotide-free solution (see
Figs. 1B and 4A). One way to reconcile these observations is
to propose (see Fig. 5) that both ATP-binding to NBF1 and
MgADP-binding to NBF2 (resulting from hydrolysis of
MgATP) are required for Mg-nucleotide stimulation of
KATP channels. In this case, loss of ATP from NBF1 would
eliminate stimulation by Mg-nucleotides, consistent with the
requirement that the NBFs are intact for stimulation to occur
[27,45].
We propose a two component mechanism for high-a⁄nity
tolbutamide inhibition of SUR1/KIR6.2 channels that explains
the selective inhibition of pancreatic L-cell versus sarcolemmal
KATP channels (Fig. 5). Sulfonylurea-binding to TMD12-17
induces a conformational change in SUR1 irrespective of
whether Mg2 and/or nucleotides are present. This conforma-
tional switch uses the N-terminus of KIR6.2 to stabilize a
long-lived closed state in which gated access of potassium
ions to the pore is denied and also disrupts the Mg-nucleo-
tide-induced stimulatory action of SUR1 on KIR6.2. The
stimulatory signal does not require the N-terminus and
normally acts to antagonize the inhibitory action of intra-
cellular nucleotides on KIR6.2. Impairment of this signal
reveals the inhibitory action of nucleotides. Nucleotide-inde-
pendent stabilization of the closed state reduces the Po by
V60%, while disrupting stimulation by Mg-nucleotides causes
a further reduction whose extent depends upon the intracel-
lular nucleotide concentration. This model accounts for the
increased e⁄cacy of sulfonylureas on SUR1/KIR6.2 channels
in vivo.
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